USP20 governs tyrosine kinase inhibitors resistance through ferroptosis evasion by targeting GPX4 in cancers

Tyrosine kinase inhibitors (TKIs) including sunitinib and sorafenib remain first-line therapies for advanced renal cell carcinoma (RCC) and lung cancer (LC), but their efficacy is limited by acquired resistance. By characterizing metabolic adaptations in TKI-resistant tumors, we identify ubiquitin-s...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Yuzhao Wang, Bo Liu, Yanxin Zhuang, Yulin Zhang, Weichao Dan, Peng Ding, Yi Wei, Chendong Guo, Mengxing Li, Chi Wang, Yelinaer Baoerbieke, Xinqi Pei, Lei Li, Yizeng Fan
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2026-05-01
Serija:	Redox Biology
Teme:	USP20 GPX4 Ferroptosis Deubiquitylation TKI resistance
Online dostop:	http://www.sciencedirect.com/science/article/pii/S2213231726000844
Oznake:	Označite Brez oznak, prvi označite!